# A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

> **NCT04152200** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 1
- Primary Hyperoxaluria

## Interventions

- **DRUG:** Lumasiran

## Key facts

- **NCT ID:** NCT04152200
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-21
- **Primary completion:** 2021-05-18
- **Final completion:** 2025-06-23
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152200, "A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04152200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*